PharmaEngine Inc. announced that the China NMPA
has granted approval for ONIVYDE Regimen for the
Treatment of Metastatic Pancreatic Cancer
Date of events
2022/04/15
To which item it meets
paragraph 53
Statement
1.Date of occurrence of the event:2022/04/15
2.Company name:PharmaEngine Inc.
3.Relationship to the Company (please enter "head office" or
"subsidiaries"):Head office
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:ONIVYDE in combination with fluorouracil (5-FU) and
leucovorin (LV) has been approved by China National Medical Products
Administration (NMPA) for the treatment of patients with metastatic
pancreatic cancer after disease progression following gemcitabine-based
therapy.
6.Countermeasures:NA
7.Any other matters that need to be specified:According to the WHO estimates
124,994 new cases of pancreatic cancer were registered China in 2020.
Pancreatic cancer has ranked as the 8th most common cancer in China.
Attachments
Original Link
Original Document
Permalink
Disclaimer
PharmaEngine Inc. published this content on 15 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 April 2022 07:19:09 UTC.
PharmaEngine, Inc. is a Taiwan-based company principally engaged in the development of new drugs, as well as the licensing and sales of products. The Company is developing three new anti-cancer drugs under the brand of ONIVYDE, which are nal-IRI, MM-398 and PEP02. The Company distributes its products mainly to overseas markets,
PHARMAENGINE, INC. 
